CD2BP2 inhibitors constitute a chemical class characterized by their capacity to selectively target and modulate the activity of the CD2 binding protein 2 (CD2BP2), a protein involved in various cellular processes. CD2BP2, also known as SIP or SIN, is a multifunctional protein that plays a crucial role in intracellular signaling and cellular dynamics. The inhibitors within this class are primarily designed to interact with specific molecular components of CD2BP2, thereby interfering with its normal functioning. By doing so, these inhibitors have to influence various cellular pathways and processes regulated by CD2BP2.
The mechanism of action of CD2BP2 inhibitors typically involves binding to specific regions or domains of CD2BP2, disrupting its interactions with other cellular proteins or molecules. This interference can result in downstream effects on cellular signaling cascades, gene expression, and protein interactions. In essence, CD2BP2 inhibitors act as molecular tools to dissect the intricate web of cellular processes regulated by CD2BP2, allowing researchers to gain insights into its functions and associated pathways. These inhibitors are invaluable in laboratory research, where they are used to elucidate the roles of CD2BP2 in diverse biological contexts. Researchers employ CD2BP2 inhibitors as valuable resources for uncovering the molecular underpinnings of cellular events and for exploring targets, although their applications are a separate consideration from their utility as research tools. Through the precise manipulation of CD2BP2 activity, this chemical class contributes to our understanding of fundamental cellular biology and provides a foundation for further scientific exploration and discovery.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Baricitinib also targets JAK1 and JAK2, inhibiting CD2BP2 by suppressing the JAK-STAT signaling pathway involved in immune and inflammatory responses. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib inhibits CD2BP2 through its action on JAK1 and JAK2, reducing cytokine-mediated inflammation in conditions like myelofibrosis and polycythemia vera. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
Filgotinib inhibits CD2BP2 by targeting JAK1, which hampers the JAK-STAT pathway, reducing inflammation in inflammatory bowel disease and rheumatoid arthritis. | ||||||
TG101348 | 936091-26-8 | sc-364740 sc-364740A | 5 mg 25 mg | $207.00 $515.00 | 6 | |
Fedratinib inhibits CD2BP2 by selectively targeting JAK2, primarily used in myeloproliferative neoplasms therapy by suppressing cytokine signaling. | ||||||